Correlation of serum immunoglobulin free light chain quantification with serum and urine immunofixation in monoclonal gammopathies

Acta Haematologica Polonica

Volumn 42, Issue 2, 2011, Pages 273-283

  Kraj, Maria ^a   Kruk, Barbara ^a   Pogłód, Ryszard ^a   Szczepiński, Andrzej ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Free light chain; MGUS; Multiple myeloma; Waldenstr m macroglobulinemia

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL LEUKEMIA; PLASMACYTOMA; PROTEIN ELECTROPHORESIS; QUANTITATIVE ANALYSIS; REMISSION; RISK FACTOR; SERUM; URINE; WALDENSTROEM MACROGLOBULINEMIA;

EID: 80755142921     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009; 55: 1517-1522.
2. Kraj M, Łukaszewicz M, Michalak T. Non productor and non - secretory multiple myeloma. Analysis of 17 cases. Acta Med Pol 1985; 26: 51-59.
3. Kraj M, Rostkowska J, Pogłód R. Clinical and laboratory analysis of cases of light chain disease. Acta Med Pol 1987; 28: 73-98.
4. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-680. (Pubitemid 32275810)
5. Drayson MT, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900-2902.
6. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437-1444. (Pubitemid 34925779)
7. Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 489-491. (Pubitemid 36173716)
8. Abraham RS, Katzmann JA, Clark RJ et al. Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119: 274-278. (Pubitemid 37047884)
9. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008; 111: 785-789.
10. Kyle RA, Durie BGM, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127.
11. Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108: 1979-1983. (Pubitemid 44395010)
12. Snozek CLH, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the International Staging System. Leukemia 2008; 22: 1933-1937.
13. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007; 137: 240-243. (Pubitemid 46537637)
14. van Rhee F, Bolejack V, HoUming K, et al. High serum - free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832.
15. Sobh M, Pharm M, Morisset S, et al. Serum kappa/lambda ratio, an independent prognostic factor at diagnosis and serum free-light chains level an early indicator of relapse/progression in multiple myeloma. Blood 2010; 116: 1218-1219. (Abstract # 2954).
16. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
17. Kumar S, Dispenzieri A, Larson D, et al. Normalization of the serum free light chain (flc) ratio is associated with superior overall survival among myeloma patients achieving immunofixation negative state: results support incorporation of serum flc ratio in stringent cr definition [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112: 1692.
18. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473. (Pubitemid 44264086)
19. Warzocha K, Kraj M, Pogłód R, Sokołowska U. The efficacy and safety of bortezomib (Velcade) in the treatment of relapsed and refractory multiple myeloma. Preliminary report. Nowotwory Journal of Oncology 2007; 57: 67e-75e.
20. Abadie JM, von Hoeven KH, Wells JM. Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis ? Am J Clin Pathol 2009: 131: 166-171.
21. Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002; 48: 655-657. (Pubitemid 34261233)
22. Dispenzieri A, Kyle R, Merlini G, et al. Internationa] Myeloma Working Group guidelines for serum - free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215-224.
23. Nowrousian MR, Brandhorst D, Sammer C, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11: 8706-8714. (Pubitemid 43005920)
24. Singhal S, Stein R, Vickrey E, Mehat J. The serum -free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood 2007; 109: 3611-3612. (Pubitemid 46572562)
25. Siegel DS, MC Bride L, Bilotti E. Inaccuracies in 24-hour urine testing for monoclonal gammopathies. Serum free light chain analysis provides a more accurate measure of light chain burden than urine protein electrophoresis. Lab Medicine 2009; 40: 341-344.
26. Fulton RB, Fernando SL. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy. Annals of Clinical Biochemistry 2009; 46: 407-412.
27. Hill PG, Forsyth JM, Rai B, Mayne S. Serum free light chains: an alternative test to urine Bence Jones proteins when screening for monoclonal gammopathies. Clin Chem 2006; 52: 1743-1748. (Pubitemid 44330709)
28. Piehler AP, Gulbrandsen N, Kierulf P, Urdal P. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem 2008; 54: 1823-1830.
29. Katzmann JA, Dispenzieri A, Kyle RA, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81: 1575-1578. (Pubitemid 44871901)
30. Katzmann JA, Dispenzieri A. Screening algorithms for monoclonal gammopathies. Clin Chem 2008; 54: 1753-1755.
31. Dispenzieri A, Zhang I, Katzmann JA, et al. Appraisal of immunoglobulin free light chains as a marker of response. Blood 2008; 111: 4908-4915.
32. Hassoun H, Reich L, Klimek VM, et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006; 132: 155-161. (Pubitemid 43381549)
33. Hajek R, Cermakova Z, Pour L, et al. Free light chain assays for early detection of resistance to bortezomib-based regimens. Haematologica 2007; 92: 93.
34. Kröger N. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. Haematologica. 2007; 92: 275-276. (Pubitemid 46852439)
35. Kucombining double acute accenthnemund A, Liebisch P, Bauchmucombining double acute accentller K. "Light-chain escape - multiple myeloma" - an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol DOI 10.1007/s00432-008-0470-7.
36. Hobbs JA, Sharp K, Harding SJ et al. Changes in M-protein at multiple myeloma relapse. Clinical Lymphoma and Myeloma 2009; 9 Suppl 1: S27 (abstract 162).
37. Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007; 92: 143-144. (Pubitemid 46232680)
38. Leleu X, Xie W, Rourke M, et al. The role of serum immunoglobulin free light chain in response and progression in Waldenstrocombining double acute accentm Macroglobulinemia. Blood 2010: 116: 1276 (Abstract # 3095).
39. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-817. (Pubitemid 41076419)